Latest Insider Transactions at Acumen Pharmaceuticals, Inc. (ABOS)
This section provides a real-time view of insider transactions for Acumen Pharmaceuticals, Inc. (ABOS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Acumen Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Acumen Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jul 06
2021
|
Daniel Joseph O Connell Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
10
-0.63%
|
$160
$16.0 P/Share
|
Jul 06
2021
|
Daniel Joseph O Connell Chief Executive Officer |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
35
+2.17%
|
$140
$4.47 P/Share
|
Jul 06
2021
|
Daniel Joseph O Connell Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
123
+7.39%
|
-
|
Jul 06
2021
|
John A Stalfort Iii Director |
BUY
Conversion of derivative security
|
Indirect |
131,595
+50.0%
|
-
|
Jul 06
2021
|
John A Stalfort Iii Director |
BUY
Open market or private purchase
|
Direct |
35,000
+16.88%
|
$560,000
$16.0 P/Share
|
Jul 06
2021
|
John A Stalfort Iii Director |
BUY
Conversion of derivative security
|
Direct |
130,180
+48.66%
|
-
|
Jul 06
2021
|
Matt Zuga CFO & Chief Business Officer |
BUY
Conversion of derivative security
|
Direct |
26,187
+50.0%
|
-
|
Jul 06
2021
|
Paul B Manning > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
3,608,469
+49.63%
|
-
|
Jul 06
2021
|
Paul B Manning > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
312,500
+8.53%
|
$5,000,000
$16.0 P/Share
|
Jul 06
2021
|
Ra Capital Management, L.P. |
BUY
Conversion of derivative security
|
Indirect |
7,895,773
+50.0%
|
-
|
Jul 06
2021
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
1,875,000
+13.21%
|
$30,000,000
$16.0 P/Share
|